ICU Medical Q1 GAAP net income $30.1M vs loss a year ago; organic revenue up 1%

ICU MEDICAL INC/DE

2026-Q1 EPS reported $1.20 revenue$530,225,000

GAAP revenue $530.2M, down 12% YoY due to IV Solutions divestiture; non-GAAP organic revenue up 1%.
GAAP gross margin improved to 39% from 35%; gross profit $206.2M vs $210.1M.
GAAP diluted EPS $1.20 vs $(0.63) loss; adjusted diluted EPS $1.97 vs $1.72.
Adjusted EBITDA $98.7M vs $99.4M; company reiterates focus on innovation and operational efficiency.
Results reflect first full quarter without IV Solutions; management highlights margin expansion and cash flow.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ICU MEDICAL INC/DE reported first quarter of 2026 results: revenue $530.2 million, net income $30.1 million, EPS $1.20 per diluted share.

Period: first quarter of 2026
Revenue: $530.2 million
Net income: $30.1 million
EPS: $1.20 per diluted share
Result: reported results

Exact text from the filing

First quarter 2026 GAAP revenue was $530.2 million, as compared to $604.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2026 was $206.2 million, as compared to $210.1 million in the same period in the prior year. GAAP gross margin for the first quarter of 2026 was 39%, as compared to 35% in the same period in the prior year. GAAP net income for the first quarter of 2026 was $30.1 million, or $1.20 per diluted share

View on SEC.gov

Browse all earnings releases →

ICU MEDICAL INC/DE filing history →

Source: SEC EDGAR

accession 0000883984-26-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.